{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:41:41Z","timestamp":1789962101795,"version":"4.0.1"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.redox.2026.104239","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:05:15Z","timestamp":1779865515000},"page":"104239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The irony of Parkinson's disease: Converging mechanisms of redox imbalance and ferroptosis"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3847-9984","authenticated-orcid":false,"given":"Lauren E.","family":"Cooke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"DiMaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-4431","authenticated-orcid":false,"given":"Marco","family":"Fazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib1","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","article-title":"Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2024","journal-title":"Lancet Healthy Longev."},{"issue":"10291","key":"10.1016\/j.redox.2026.104239_bib2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.redox.2026.104239_bib3","author":"Foundation"},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s42003-023-05548-w","article-title":"Omics data integration suggests a potential idiopathic Parkinson's disease signature","volume":"6","author":"Zagare","year":"2023","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib5","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1097\/MS9.0000000000001142","article-title":"Parkinson's disease updates: addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment","volume":"85","author":"Prajjwal","year":"2023","journal-title":"Ann. Med. Surg."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JPD-212922","article-title":"Preventing Parkinson's Disease: an environmental agenda","volume":"12","author":"De Miranda","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.redox.2026.104239_bib7","article-title":"Parkinson's disease and the environment","volume":"10","author":"Nicole Ball","year":"2019","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1289\/ehp.1002839","article-title":"Rotenone, paraquat, and Parkinson's disease","volume":"119","author":"Tanner","year":"2011","journal-title":"Environ. Health Perspect."},{"issue":"10423","key":"10.1016\/j.redox.2026.104239_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/mp.2013.3","article-title":"Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease","volume":"19","author":"Drui","year":"2014","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mds.25096","article-title":"New synaptic and molecular targets for neuroprotection in Parkinson's disease","volume":"28","author":"Calabresi","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson's disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.redox.2026.104239_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fnagi.2017.00151","article-title":"Distinct role of striatal functional connectivity and dopaminergic loss in parkinson's symptoms","volume":"9","author":"Dukart","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson's disease and relevant therapeutic options: a review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neurosci"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.redox.2026.104239_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fneur.2020.00395","article-title":"Clinical and imaging markers of prodromal Parkinson's Disease","volume":"11","author":"Hustad","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.57.3.456","article-title":"Frequency of bowel movements and the future risk of Parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.redox.2026.104239_bib18","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1212\/WNL.0000000000001684","article-title":"Anna Nordstr\u00f6m, PhD, and Peter Nordstr\u00f6m, PhD, Depression and subsequent risk of Parkinson disease","volume":"84","author":"Helena Gustafsson","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.0000000000001364","article-title":"Parkinson risk in idiopathic REM sleep behavior disorder","volume":"84","author":"Postuma","year":"2015","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.redox.2026.104239_bib20","doi-asserted-by":"crossref","first-page":"e2157","DOI":"10.1212\/WNL.0000000000008567","article-title":"Physical activity and prodromal features of Parkinson disease","volume":"93","author":"Hughes","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.redox.2026.104239_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.nicl.2017.04.011","article-title":"Neuroimaging in pre-motor Parkinson's disease","volume":"15","author":"Barber","year":"2017","journal-title":"Neuroimage, Clin."},{"key":"10.1016\/j.redox.2026.104239_bib22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0000000000002509","article-title":"Levodopa therapy for Parkinson disease A look backward and forward","volume":"86","author":"LeWitt","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040612","article-title":"Treatment options for motor and non-motor symptoms of Parkinson's Disease","volume":"11","author":"Church","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2025.100274","article-title":"Current therapeutic strategies in Parkinson's disease: future perspectives","volume":"48","author":"Kim","year":"2025","journal-title":"Mol. Cells"},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archneur.64.8.1083","article-title":"Treatment options in the modern management of Parkinson disease","volume":"64","author":"Schapira","year":"2007","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/mdc3.13957","article-title":"Challenges in managing nonmotor symptoms of Parkinson's Disease in low-resourced settings with unavailability of newer drugs","volume":"11","author":"Aldaajani","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/ars.2010.3629","article-title":"Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults","volume":"15","author":"Horowitz","year":"2011","journal-title":"Antioxidants Redox Signal."},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1089\/ars.2010.3386","article-title":"Neuronal calcium homeostasis and dysregulation","volume":"14","author":"Gleichmann","year":"2011","journal-title":"Antioxidants Redox Signal."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41422-023-00788-1","article-title":"Mitochondria-localized cGAS suppresses ferroptosis to promote cancer progression","volume":"33","author":"Qiu","year":"2023","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib31","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib32","first-page":"273","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism","volume":"171","author":"Stockwell","year":"2017","journal-title":"Redox Biology, and Disease, Cell"},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165228","article-title":"Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons","volume":"133","author":"Sun","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2026.104239_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2016.15","article-title":"Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson's substantia nigra","volume":"1","author":"Ayton","year":"2016","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1471-4159.1990.tb08814.x","article-title":"Decreased ferritin levels in brain in Parkinson's disease","volume":"55","author":"Dexter","year":"1990","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib36","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2026.5790","article-title":"Ferritin in ferroptosis: implications for neurodegenerative diseases","volume":"57","author":"Chen","year":"2026","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib37","article-title":"Ferroptosis-related factors in the substantia nigra are associated with Parkinson's disease","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.redox.2026.104239_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1134\/S1819712419040020","article-title":"Lipid peroxidation products in the blood plasma of patients with parkinson's disease as possible biomarkers of different stages of the disease","volume":"13","author":"Fedorova","year":"2019","journal-title":"Neurochem. J."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41531-023-00502-3","article-title":"Neuroprotective actions of a fatty acid nitroalkene in Parkinson's disease","volume":"9","author":"Di Maio","year":"2023","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061456","article-title":"Iron and chelation in biochemistry and medicine: new approaches to controlling iron metabolism and treating related diseases","volume":"9","author":"Kontoghiorghes Gj","year":"2020","journal-title":"Cells"},{"issue":"3\u20134","key":"10.1016\/j.redox.2026.104239_bib41","first-page":"489","article-title":"The chelatable iron pool in living cells: a methodically defined quantity","volume":"383","author":"Petrat F","year":"2002","journal-title":"Biol. Chem."},{"issue":"5880","key":"10.1016\/j.redox.2026.104239_bib42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1126\/science.1157643","article-title":"A cytosolic iron chaperone that delivers iron to ferritin","volume":"320","author":"Shi","year":"2008","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","article-title":"Regulation of iron transport and the role of transferrin","volume":"1820","author":"Gkouvatsos","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1007\/s12035-020-02277-7","article-title":"New insights into the role of ferritin in iron homeostasis and neurodegenerative diseases","volume":"58","author":"Zhang N","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"23","key":"10.1016\/j.redox.2026.104239_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233829","article-title":"Iron brain menace: the involvement of ferroptosis in parkinson disease","volume":"11","author":"Lin","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxidants Redox Signal."},{"issue":"22","key":"10.1016\/j.redox.2026.104239_bib48","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of deferiprone in Parkinson's Disease","volume":"387","author":"Devos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.redox.2026.104239_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800311","article-title":"GPX4 at the crossroads of lipid homeostasis and ferroptosis","volume":"19","author":"Forcina","year":"2019","journal-title":"Proteomics"},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib50","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41467-020-15065-7","article-title":"Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease","volume":"11","author":"Vallerga","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41531-025-00911-6","article-title":"Nigrostriatal iron accumulation in the progression of Parkinson's disease","volume":"11","author":"L\u00f3pez-Aguirre","year":"2025","journal-title":"npj Parkinson's Dis."},{"issue":"5\u20136","key":"10.1016\/j.redox.2026.104239_bib52","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00702-022-02505-5","article-title":"A brief history of brain iron accumulation in Parkinson disease and related disorders","volume":"129","author":"Foley","year":"2022","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib53","article-title":"Voluntary exercise alleviates neural functional deficits in Parkinson's disease mice by inhibiting microglial ferroptosis via SLC7A11\/ALOX12 axis","volume":"11","author":"Xu J","year":"2025","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12061257","article-title":"N-Acetylcysteine treatment May compensate motor impairments through dopaminergic transmission modulation in a striatal 6-Hydroxydopamine Parkinson's Disease rat model","volume":"12","author":"Caridade-Silva","year":"2023","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/jnr.20107","article-title":"Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration","volume":"76","author":"Mu\u00f1oz","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.redox.2026.104239_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainresbull.2015.02.007","article-title":"N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: an investigation into the interaction of parkin and Drp1 proteins","volume":"113","author":"Rahimmi","year":"2015","journal-title":"Brain Res. Bull."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.parkreldis.2015.02.020","article-title":"Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease","volume":"21","author":"Katz","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157602","article-title":"N-Acetyl cysteine May support dopamine neurons in Parkinson's Disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/mds.22401","article-title":"Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104239_bib61","author":"Mischley"},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.chroma.2007.10.055","article-title":"Determination of the ubiquinol-10 and ubiquinone-10 (coenzyme Q10) in human serum by liquid chromatography tandem mass spectrometry to evaluate the oxidative stress","volume":"1175","author":"Ruiz-Jim\u00e9nez","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.redox.2026.104239_bib63","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0098-2997(97)00031-9","article-title":"Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis?","volume":"18","author":"Thomas","year":"1997","journal-title":"Mol. Aspect. Med."},{"issue":"7784","key":"10.1016\/j.redox.2026.104239_bib64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.redox.2026.104239_bib65","article-title":"System x(c) (-)\/GSH\/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.redox.2026.104239_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1226044","article-title":"ROS induced lipid peroxidation and their role in ferroptosis","volume":"11","author":"Endale","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib67","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.50.3.793","article-title":"Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients","volume":"50","author":"Shults Cw","year":"1998","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib68","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Parkinson Study Group","year":"2014","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14082748","article-title":"Coenzyme Q10 and the blood-brain barrier: an overview","volume":"14","author":"Mantle","year":"2025","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib70","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1016\/j.apsb.2023.07.010","article-title":"Oxidative stress, the blood-brain barrier and neurodegenerative diseases: the critical beneficial role of dietary antioxidants","volume":"13","author":"Feng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib71","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1038\/s41467-024-51996-1","article-title":"Suppression of ferroptosis by vitamin A or radical-trapping antioxidants is essential for neuronal development","volume":"15","author":"Tschuck","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2026.104239_bib72","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2023.06.003","article-title":"Retinoic acid protects against lipopolysaccharide-induced ferroptotic liver injury and iron disorders by regulating Nrf2\/HO-1 and RAR\u03b2 signaling","volume":"205","author":"Lai X","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"41","key":"10.1016\/j.redox.2026.104239_bib73","article-title":"Dietary \u03b2-carotene and vitamin A and risk of Parkinson disease: a protocol for systematic review and meta-analysis","volume":"101","author":"Wu","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.redox.2026.104239_bib74","author":"Philippe Diaz"},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201369","article-title":"Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase","volume":"13","author":"Hinman","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib76","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11064-021-03483-y","article-title":"Vitamin E exerts neuroprotective effects in pentylenetetrazole kindling epilepsy via suppression of ferroptosis","volume":"47","author":"Zhang","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.redox.2026.104239_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116734","article-title":"Alpha-tocopherol inhibits ferroptosis and promotes neural function recovery in rats with spinal cord injury via downregulating Alox15","volume":"175","author":"Zhu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib78","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group","volume":"46","year":"1989","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.redox.2026.104239_bib79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuint.2017.03.014","article-title":"The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"108","author":"Taghizadeh","year":"2017","journal-title":"Neurochem. Int."},{"issue":"7924","key":"10.1016\/j.redox.2026.104239_bib80","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05022-3","article-title":"A non-canonical vitamin K cycle is a potent ferroptosis suppressor","volume":"608","author":"Mishima","year":"2022","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294763","article-title":"Vitamin K2 (MK-7) attenuates LPS-induced acute lung injury via inhibiting inflammation, apoptosis, and ferroptosis","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib82","article-title":"Vitamin K1 inhibits ferroptosis and counteracts a detrimental effect of phenprocoumon in experimental acute kidney injury","volume":"79","author":"Benedikt Kolbrink","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.redox.2026.104239_bib83","article-title":"Role of Nrf2 in Parkinson's Disease: toward new perspectives","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib85","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1007\/s12035-018-0961-8","article-title":"Alterations in System x(c)(-) expression in the retina of type 1 diabetic rats and the role of Nrf2","volume":"55","author":"Carpi-Santos","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12906-023-03967-0","article-title":"Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson's disease via inhibiting oxidative stress and ferroptosis","volume":"23","author":"Li","year":"2023","journal-title":"BMC Complement. Med. Ther."},{"key":"10.1016\/j.redox.2026.104239_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175875","article-title":"Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease","volume":"954","author":"Mansour","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/ars.2015.6549","article-title":"Repurposing the NRF2 activator Dimethyl fumarate as therapy against synucleinopathy in Parkinson's Disease","volume":"25","author":"Lastres-Becker","year":"2016","journal-title":"Antioxidants Redox Signal."},{"issue":"12","key":"10.1016\/j.redox.2026.104239_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122565","article-title":"Pathological functions of LRRK2 in Parkinson's Disease","volume":"9","author":"Jeong","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1042\/BCJ20253099","article-title":"Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease","volume":"482","author":"Dzamko","year":"2025","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib92","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BST20180462","article-title":"LRRK2 links genetic and sporadic Parkinson's disease","volume":"47","author":"Kluss","year":"2019","journal-title":"Biochem. Soc. Trans."},{"issue":"43","key":"10.1016\/j.redox.2026.104239_bib93","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205492119","article-title":"Lysosomal positioning regulates Rab10 phosphorylation at LRRK2(+) lysosomes","volume":"119","author":"Kluss","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib94","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202302067","article-title":"The V-ATPase-ATG16L1 axis recruits LRRK2 to facilitate the lysosomal stress response","volume":"223","author":"Eguchi","year":"2024","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042378","article-title":"Ferritinophagy and \u03b1-Synuclein: pharmacological targeting of autophagy to restore iron regulation in Parkinson's Disease","volume":"23","author":"Boag","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8067","key":"10.1016\/j.redox.2026.104239_bib96","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-025-08974-4","article-title":"Activation of lysosomal iron triggers ferroptosis in cancer","volume":"642","author":"Ca\u00f1eque","year":"2025","journal-title":"Nature"},{"issue":"451","key":"10.1016\/j.redox.2026.104239_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"767","key":"10.1016\/j.redox.2026.104239_bib98","doi-asserted-by":"crossref","first-page":"eadl3438","DOI":"10.1126\/scitranslmed.adl3438","article-title":"LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease","volume":"16","author":"Keeney","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib99","article-title":"LRRK2 regulates ferroptosis through the system Xc-GSH\u2013GPX4 pathway in the neuroinflammatory mechanism of Parkinson's disease","volume":"239","author":"Zijian Zheng","year":"2024","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib100","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1007\/s10753-025-02291-8","article-title":"LRRK2 mediates \u03b1-Synuclein-Induced neuroinflammation and ferroptosis through the p62-Keap1-Nrf2 pathway in Parkinson's Disease","volume":"48","author":"Liu X","year":"2025","journal-title":"Inflammation"},{"key":"10.1016\/j.redox.2026.104239_bib101","article-title":"Parkinson's disease LRRK2 mutations dysregulate iron homeostasis and promote oxidative stress and ferroptosis in human neurons and astrocytes","volume":"2025.09.26","author":"Mamais","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.redox.2026.104239_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115475","article-title":"Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives","volume":"256","author":"Hu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.redox.2026.104239_bib103","series-title":"New Clinical Trials Targeting the LRRK2 Gene","author":"Foundation","year":"2022"},{"key":"10.1016\/j.redox.2026.104239_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101512","article-title":"NADPH oxidases: current aspects and tools","volume":"34","author":"Schr\u00f6der","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104239_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105754","article-title":"NADPH oxidase 2 activity in Parkinson's disease","volume":"170","author":"Keeney","year":"2022","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib106","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41420-021-00483-3","article-title":"Molecular mechanism of cell ferroptosis and research progress in regulation of ferroptosis by noncoding RNAs in tumor cells","volume":"7","author":"Xie","year":"2021","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib107","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41419-022-04775-z","article-title":"Interaction between macrophages and ferroptosis","volume":"13","author":"Yang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.redox.2026.104239_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103369","article-title":"Microglial CR3 promotes neuron ferroptosis via NOX2-mediated iron deposition in rotenone-induced experimental models of Parkinson's disease","volume":"77","author":"Wang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104239_bib109","article-title":"Neuronal NADPH oxidase 2 in Parkinson's disease pathogenesis","author":"Keeney","year":"2021","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib110","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1039\/c3md00061c","article-title":"Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors","volume":"4","author":"Cifuentes-Pagano","year":"2013","journal-title":"Medchemcomm"},{"issue":"12","key":"10.1016\/j.redox.2026.104239_bib111","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41419-024-07258-5","article-title":"Mitochondria-targeted oligomeric \u03b1-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson's disease and parkinsonism-dementia of Guam","volume":"15","author":"Vasquez","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nchembio.2238","article-title":"Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis","volume":"13","author":"Kagan","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"12","key":"10.1016\/j.redox.2026.104239_bib113","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"issue":"Pt 1","key":"10.1016\/j.redox.2026.104239_bib114","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/bj20021525","article-title":"1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide","volume":"371","author":"Kalivendi","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.redox.2026.104239_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-9-17","article-title":"The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons","volume":"9","author":"Lu","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib116","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbadis.2012.07.009","article-title":"The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease","volume":"1832","author":"Solesio","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib117","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.freeradbiomed.2010.08.028","article-title":"Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model","volume":"49","author":"Ghosh","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib118","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","article-title":"A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease","volume":"25","author":"Snow","year":"2010","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111231","article-title":"Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane composition","volume":"40","author":"Mahoney-Sanchez","year":"2022","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib120","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41418-020-0542-z","article-title":"Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation","volume":"27","author":"Angelova","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.redox.2026.104239_bib121","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2022.09.015","article-title":"\u03b1-Syn overexpression, NRF2 suppression, and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson's disease","volume":"192","author":"A","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104239_bib122","author":"Therapeutics"},{"key":"10.1016\/j.redox.2026.104239_bib123","author":"Annovis"},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib124","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib126","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JPD-212594","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-Synuclein with PD03A in patients with early Parkinson's Disease: a randomized, Placebo-Controlled, phase 1 Study","volume":"11","author":"Poewe","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib127","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an Anti-\u03b1-Synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.redox.2026.104239_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","article-title":"A phase II Study to evaluate the safety and efficacy of Prasinezumab in early Parkinson's Disease (PASADENA): Rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's Disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib130","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.redox.2026.104239_bib131","doi-asserted-by":"crossref","first-page":"e929","DOI":"10.1016\/j.wneu.2022.08.121","article-title":"Metformin Attenuates ferroptosis and promotes functional recovery of spinal cord injury","volume":"167","author":"Wang","year":"2022","journal-title":"World Neurosurg."},{"key":"10.1016\/j.redox.2026.104239_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108065","article-title":"Metformin attenuates cadmium-induced neuronal apoptosis in vitro via blocking ROS-dependent PP5\/AMPK-JNK signaling pathway","volume":"175","author":"Chen","year":"2020","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.redox.2026.104239_bib133","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.1002\/jcp.28337","article-title":"Metformin protects PC12 cells and hippocampal neurons from H(2) O (2) -induced oxidative damage through activation of AMPK pathway","volume":"234","author":"Zhao","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.redox.2026.104239_bib134","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.redox.2026.104239_bib136","author":"Parkinson's"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib137","article-title":"GLP-1 receptor agonists alleviate Diabetic Kidney Injury via \u03b2-Klotho-Mediated ferroptosis inhibition","volume":"12","author":"Tian","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.redox.2026.104239_bib138","article-title":"The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity","volume":"19","author":"Zhang","year":"2025","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.redox.2026.104239_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"issue":"10103","key":"10.1016\/j.redox.2026.104239_bib140","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib141","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the Exenatide-PD trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jnc.12767","article-title":"The high-affinity D2\/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease","volume":"131","author":"Shah","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.redox.2026.104239_bib143","article-title":"Endothelial CYB5R1 is a Coenzyme Q reductase that suppresses ferroptosis and atherosclerosis","author":"Hall","year":"2025","journal-title":"Res Sq"},{"key":"10.1016\/j.redox.2026.104239_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137346","article-title":"Alpha lipoic acid ameliorates motor deficits by inhibiting ferroptosis in Parkinson's disease","volume":"810","author":"Zheng","year":"2023","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","article-title":"Idebenone ameliorates rotenone-induced Parkinson's Disease in rats through decreasing lipid peroxidation","volume":"46","author":"Avc\u0131","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.redox.2026.104239_bib146","article-title":"Resveratrol attenuates rotenone-induced inflammation and oxidative stress via STAT1 and Nrf2\/Keap1\/SLC7A11 pathway in a microglia cell line","volume":"225","author":"Li","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.redox.2026.104239_bib147","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7769355","article-title":"Quercetin protects against MPP(+)\/MPTP-Induced dopaminergic neuron death in Parkinson's Disease by inhibiting ferroptosis","volume":"2022","author":"Lin","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib148","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12264-012-1238-2","article-title":"Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease","volume":"28","author":"Du","year":"2012","journal-title":"Neurosci. Bull."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib149","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jnr.23307","article-title":"Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-\u03baB, ERK, and JNK","volume":"92","author":"Lee","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.redox.2026.104239_bib150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2017.06.031","article-title":"Baicalein blocks \u03b1-synuclein secretion from SN4741 cells and facilitates \u03b1-synuclein polymerization to big complex","volume":"655","author":"Li","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"21","key":"10.1016\/j.redox.2026.104239_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/nu14214599","article-title":"The ferroptosis inhibitor Liproxstatin-1 ameliorates LPS-Induced cognitive impairment in mice","volume":"14","author":"Li","year":"2022","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib152","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11064-021-03262-9","article-title":"Benefits of iron chelators in the treatment of Parkinson's Disease","volume":"46","author":"Zeng","year":"2021","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib153","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s12035-021-02320-1","article-title":"Thioredoxin-1 rescues MPP(+)\/MPTP-Induced ferroptosis by increasing glutathione peroxidase 4","volume":"58","author":"Bai","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.redox.2026.104239_bib154","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4103\/1673-5374.371381","article-title":"Rapamycin reverses ferroptosis by increasing autophagy in MPTP\/MPP(+)-induced models of Parkinson's disease","volume":"18","author":"Liu","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","article-title":"The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease","volume":"5","author":"Finkelstein","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2003.09.005","article-title":"Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats","volume":"46","author":"Shachar","year":"2004","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.redox.2026.104239_bib157","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1096\/fj.07-8386com","article-title":"Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators","volume":"21","author":"Zhu","year":"2007","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102431","article-title":"Apoferritin improves motor deficits in MPTP-treated mice by regulating brain iron metabolism and ferroptosis","volume":"24","author":"Song","year":"2021","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.redox.2026.104239_bib159","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/cn400106n","article-title":"D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model","volume":"4","author":"Santra","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib160","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14607","article-title":"Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"30","author":"Negida","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib162","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease","volume":"68","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib163","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.parkreldis.2015.05.022","article-title":"Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease","volume":"21","author":"Yoritaka","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib164","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's Disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104239_bib165","author":"Ciccone"},{"key":"10.1016\/j.redox.2026.104239_bib166","author":"Kosikowski"},{"key":"10.1016\/j.redox.2026.104239_bib167","author":"Waanders"},{"issue":"4","key":"10.1016\/j.redox.2026.104239_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"issue":"39","key":"10.1016\/j.redox.2026.104239_bib169","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.redox.2026.104239_bib170","author":"Carvalho"},{"key":"10.1016\/j.redox.2026.104239_bib171","author":"Healthcare"},{"key":"10.1016\/j.redox.2026.104239_bib173","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.redox.2026.104239_bib174","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.redox.2026.104239_bib175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/psp4.12538","article-title":"Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain","volume":"9","author":"Kuchimanchi","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib176","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in early Parkinson's Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.redox.2026.104239_bib177","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.redox.2026.104239_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.redox.2026.104239_bib179","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104239_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"17","key":"10.1016\/j.redox.2026.104239_bib181","article-title":"Reducing \u03b1-Synuclein in Human CSF; an evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI1341, an \u03b1-Synuclein-specific antibody","volume":"100","author":"Craig Shering","year":"2023","journal-title":"Healthy Volunteers and Parkinson\u2019s Disease Patients (P1-11.007), Neurology"},{"issue":"3","key":"10.1016\/j.redox.2026.104239_bib182","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated \u03b1-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"28","key":"10.1016\/j.redox.2026.104239_bib183","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.redox.2026.104239_bib184","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104239_bib185","author":"Hoffman"},{"issue":"9","key":"10.1016\/j.redox.2026.104239_bib186","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.redox.2026.104239_bib187","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A phase 1B trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"den Heijer","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104239_bib190","author":"Sciences"}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:45:38Z","timestamp":1785224738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231726002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":186,"alternative-id":["S2213231726002375"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2026.104239","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The irony of Parkinson's disease: Converging mechanisms of redox imbalance and ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2026.104239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104239"}}